The Taiwanese continuous glucose monitoring (CGM) Market is projected to grow at a CAGR of 17.73% over the forecast period, increasing from US$9.034 million in 2025 to reach US$20.435 million by 2030.
Continuous glucose monitoring (CGM) is a wearable medical device designed to monitor continuously blood sugar levels. continuously, catering to It is used by individuals with both type 1 and type 2 diabetes. In Taiwan, the CGM market is experiencing significant growth, driven by various factors.
Key drivers include the growing prevalence of diabetes, a heightened awareness and acceptance of CGM technology, robust government support, and policy initiatives. Additionally, the increasing disposable income and a growing focus on healthcare contribute to the market's upward trajectory. CGM devices, like other innovative monitoring tools, play a pivotal role in transforming patient care. They empower "remote" patients, allowing them to leverage monitoring devices and wearable sensors, such as continuous glucose monitoring systems (CGMS).
These devices not only collect crucial healthcare data but also enable the transmission of this information to relatives and healthcare providers. This facilitates timely interventions, potentially reducing the need for hospital visits. Globally, MicroTech CGMS has proven instrumental in aiding thousands of patients through remote monitoring.
In Taiwan, numerous companies, such as Bionime, are making significant strides in the CGM market. In October 2023, Bionime Corporation received approval from the TFDA (Taiwan FDA). The iFree Continuous Glucose Monitoring System (iFree CGM) is for detecting glycemic trends and managing glucose levels. It can help to detect hyperglycemia and hypoglycemia. iFree CGM can benefit not only diabetes patients but also people who need it for glucose management.
The impaired glucose tolerance (IGT) estimates (20-79 y), the age-adjusted comparative prevalence of IGT in Taiwan was 11.5% in 2021, likely to be 12.4 % in 2030, and 12.8 % in 2045. Due to this, the CGM market in Taiwan is poised for immense growth, and capitalizing on these driving forces is imperative for sustained expansion. This strategic approach not only ensures market growth but also plays a vital role in enhancing diabetes management for thousands of individuals in Taiwan.
While increased awareness and improved diagnostics have contributed to higher detection rates, the numbers are expected to rise further due to urbanization, an aging population, and persistently unhealthy lifestyles. Traditionally, diabetes management in Taiwan heavily relied on finger-prick glucometers. However, CGM Continuous Glucose Monitoring has emerged as a transformative tool, providing real-time glucose data and trend analysis. This not only facilitates better glycemic control but also enhances the overall quality of life for individuals managing diabetes.
The growing recognition of these advantages, coupled with marketing efforts by CGM manufacturers, is propelling the adoption of CGM technology in Taiwan. This shift in approach holds promise for improving diabetes management outcomes amidst the rising challenges posed by the escalating rates of Type 2 diabetes in the country.
Continuous glucose monitoring (CGM) is a wearable medical device designed to monitor continuously blood sugar levels. continuously, catering to It is used by individuals with both type 1 and type 2 diabetes. In Taiwan, the CGM market is experiencing significant growth, driven by various factors.
Key drivers include the growing prevalence of diabetes, a heightened awareness and acceptance of CGM technology, robust government support, and policy initiatives. Additionally, the increasing disposable income and a growing focus on healthcare contribute to the market's upward trajectory. CGM devices, like other innovative monitoring tools, play a pivotal role in transforming patient care. They empower "remote" patients, allowing them to leverage monitoring devices and wearable sensors, such as continuous glucose monitoring systems (CGMS).
These devices not only collect crucial healthcare data but also enable the transmission of this information to relatives and healthcare providers. This facilitates timely interventions, potentially reducing the need for hospital visits. Globally, MicroTech CGMS has proven instrumental in aiding thousands of patients through remote monitoring.
In Taiwan, numerous companies, such as Bionime, are making significant strides in the CGM market. In October 2023, Bionime Corporation received approval from the TFDA (Taiwan FDA). The iFree Continuous Glucose Monitoring System (iFree CGM) is for detecting glycemic trends and managing glucose levels. It can help to detect hyperglycemia and hypoglycemia. iFree CGM can benefit not only diabetes patients but also people who need it for glucose management.
The impaired glucose tolerance (IGT) estimates (20-79 y), the age-adjusted comparative prevalence of IGT in Taiwan was 11.5% in 2021, likely to be 12.4 % in 2030, and 12.8 % in 2045. Due to this, the CGM market in Taiwan is poised for immense growth, and capitalizing on these driving forces is imperative for sustained expansion. This strategic approach not only ensures market growth but also plays a vital role in enhancing diabetes management for thousands of individuals in Taiwan.
Taiwan continuous glucose monitoring market drivers
Rising diabetic cases in Taiwan propel the demand
The prevalence of Type 2 diabetes in Taiwan has experienced a significant surge over the past few decades. This alarming increase is primarily attributed to unhealthy lifestyles characterized by diets high in sugar and fat, coupled with insufficient physical activity. In 2021, the number of individuals aged 20-79 with diabetes was 2,457.2 (in 1,000s), a figure projected to escalate to 2,979.4 (in 1,000s) by 2030, and 3,030.7 (in 1,000s) by 2045 as per estimates from the International Diabetes Federation.While increased awareness and improved diagnostics have contributed to higher detection rates, the numbers are expected to rise further due to urbanization, an aging population, and persistently unhealthy lifestyles. Traditionally, diabetes management in Taiwan heavily relied on finger-prick glucometers. However, CGM Continuous Glucose Monitoring has emerged as a transformative tool, providing real-time glucose data and trend analysis. This not only facilitates better glycemic control but also enhances the overall quality of life for individuals managing diabetes.
The growing recognition of these advantages, coupled with marketing efforts by CGM manufacturers, is propelling the adoption of CGM technology in Taiwan. This shift in approach holds promise for improving diabetes management outcomes amidst the rising challenges posed by the escalating rates of Type 2 diabetes in the country.
Reasons for buying this report:
- Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub-segments.
- Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
- Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
- Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
- Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.
What do businesses use our reports for?
Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive IntelligenceReport Coverage:
- Historical data & forecasts from 2022 to 2030
- Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
- Competitive Positioning, Strategies, and Market Share Analysis
- Revenue Growth and Forecast Assessment of segments and regions including countries
- Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)
Taiwan's Continuous Glucose Monitoring Market is analyzed into the following segments:
By Application
- Diabetes Patients
- Critical Patients
By End-User Industry
- Hospitals
- Diagnostic Centers & Clinics
- Home Care
By Gender
- Male
- Female
By Age
- Greater than 20 years
- Less than 20 years
By Type
- Real-time CGM
- Intermittently Scanned CGM
Table of Contents
1. INTRODUCTION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
5. TAIWAN CONTINUOUS GLUCOSE MONITORING (CGM) BY APPLICATION
6. TAIWAN CONTINUOUS GLUCOSE MONITORING (CGM) BY END-USER INDUSTRY
7. TAIWAN CONTINUOUS GLUCOSE MONITORING (CGM) BY GENDER
8. TAIWAN CONTINUOUS GLUCOSE MONITORING (CGM) MARKET BY AGE
9. TAIWAN CONTINUOUS GLUCOSE MONITORING (CGM) MARKET BY TYPE
10. COMPETITIVE ENVIRONMENT AND ANALYSIS
11. COMPANY PROFILES
Companies Mentioned
- Abbott Laboratories
- Medtronic plc
- Roche Diabetes Care, Inc.
- Tandem Diabetes Care, Inc.
- ARKRAY Inc.
- Taidoc Technology Corporation
- Bionime Corporation (Ypsomed AG)
- Novo Nordisk A/S
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 100 |
Published | December 2024 |
Forecast Period | 2025 - 2030 |
Estimated Market Value ( USD | $ 9.03 Million |
Forecasted Market Value ( USD | $ 20.44 Million |
Compound Annual Growth Rate | 17.7% |
Regions Covered | Taiwan |
No. of Companies Mentioned | 8 |